Get started
Author

Takafumi Ishii

Observed name: Ishii, Takafumi
ORCID: 0009-0005-0167-3228
Observed ORCID: 0009-0005-0167-3228
OpenAlex ID: A5068208958
Towards universal neural network potential for material discovery applicable to arbitrary combination of 45 elements
2022 · So Takamoto, Chikashi Shinagawa, et al. · Nature Communications · 524
PDF
FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al. · Cancer Research Communications · 8
PDF
High-temperature multi-element 2021 (HME21) dataset
2022 · Takamoto, So, Shinagawa, Chikashi, et al. · Figshare · 4
TABLE 1 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
FIGURE 1 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
TABLE 2 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
FIGURE 4 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Figure S4 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Figure S1 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
FIGURE 2 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
FIGURE 3 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Figure S2 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Data from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Table S3 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
PDF
Table S1 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
PDF
Table S2 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
PDF
Figure S3 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Table S5 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
PDF
FIGURE 5 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Table S4 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
PDF
Data from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Works count: 21
Citation count: 536
H-index: 3
I10-index: 1
Year
Topic
Type